{"name":"Vaxart","slug":"vaxart","ticker":"","exchange":"","domain":"","description":"Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":237258000,"revenueGrowth":726.7,"grossMargin":0,"rdSpend":201576000,"netIncome":16327000,"cash":186079000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Fluzone®","genericName":"Fluzone®","slug":"fluzone","indication":"Other","status":"marketed"},{"name":"VXA G1.1 NN-T","genericName":"VXA G1.1 NN-T","slug":"vxa-g1-1-nn-t","indication":"Other","status":"phase_1"},{"name":"VXA-A1.1 Oral Vaccine","genericName":"VXA-A1.1 Oral Vaccine","slug":"vxa-a1-1-oral-vaccine","indication":"Other","status":"phase_1"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AP611074 5% gel","genericName":"AP611074 5% gel","slug":"ap611074-5-gel","indication":"Investigational immunomodulatory indication (specific indication not publicly disclosed)","status":"phase_2"}]}],"pipeline":[{"name":"AP611074 5% gel","genericName":"AP611074 5% gel","slug":"ap611074-5-gel","phase":"phase_2","mechanism":"AP611074 is a topical immunomodulatory agent designed to enhance local immune responses in the skin.","indications":["Investigational immunomodulatory indication (specific indication not publicly disclosed)"],"catalyst":""},{"name":"Fluzone®","genericName":"Fluzone®","slug":"fluzone","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"VXA G1.1 NN-T","genericName":"VXA G1.1 NN-T","slug":"vxa-g1-1-nn-t","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"VXA-A1.1 Oral Vaccine","genericName":"VXA-A1.1 Oral Vaccine","slug":"vxa-a1-1-oral-vaccine","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-13","type":"earnings","source":"simplywall.st","summary":"Vaxart (VXRT) Revenue Surge To US$72.4 Million Tests Bearish Decline Narrative - simplywall.st","headline":"Vaxart (VXRT) Revenue Surge To US$72.4 Million Tests Bearish Decline Narrative","sentiment":"negative"},{"date":"2026-03-13","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: FORM 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBHRU9FSEdEOE5uMnNTNldGTmUyR2NpVVRIOEFCZlE2M1c1a0pnVGx2X3hCY1FBZVI4NTVqVW41UUJPakhiYWUxdWxDRHNDb0ZvVG5GbjdOVGRFZjVsUExUdWhNbXZlcmJpY2NsTGJ4bkVPcjJfLW9BRFBR?oc=5","date":"2025-12-24","type":"deal","source":"pharmaphorum","summary":"Sanofi swoops on Dynavax with $2.5bn takeover deal - pharmaphorum","headline":"Sanofi swoops on Dynavax with $2.5bn takeover deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPa255V1gwWGNuT2ZlSnVoZ0dscmhIelBDeFRIdXgtOVdFN1NVZXBWV2hvTEtILUo2V1laeXJGb2hKVTRuMzk4bzVkNHJZU3Z0RDYtdVV2SVh2YUFDVnlldmtEaTRkN0FXZi1HNm5LQkRzYlJNcm9pcUtISVBtbUZTM2RpOURFUlFpcnNhX1RtTzhZdnpXMEZTbVEwQnZDVU9rSHc?oc=5","date":"2025-11-07","type":"trial","source":"Endpoints News","summary":"Dyne changes plans for DM1 drug again; Dynavax licenses Vaxart’s Covid vaccine - Endpoints News","headline":"Dyne changes plans for DM1 drug again; Dynavax licenses Vaxart’s Covid vaccine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQOVBBcVkyRm9YRE9FSlJMd1FZWnpYbC1CcWhsbFNlTUhwblZfRlFCRVBOQmxtS2l1VF9wLWFUdWwyRXh5a29YaGN4bEJ2VlBNUnhPRlEtbEV2eU1lN0FQSHZ1UVhkQnR5d3c0LTJ3RTMyWmZlcnUyQXJWTVRNaTRzOUxpa0RQX1VlNzlrOUxGa25pbTJra2c?oc=5","date":"2025-11-06","type":"pipeline","source":"Fierce Biotech","summary":"Dynavax pays Vaxart $30M for oral COVID-19 vaccine program - Fierce Biotech","headline":"Dynavax pays Vaxart $30M for oral COVID-19 vaccine program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNMVdPVk1mWW9GTV9iRFZMZEVQTjV4d01LajBsVmZIYlJCdzF3cHhIam9qdEtyUVQ1N1VvY3A1R2xuMi0tWmFocFdOUk4xQ3ZlRUh4d1lybUlENmJnd2JCSGRGVF9VaEY0NUY5UkxhVjdfRXBjazRMdjg0bUQ4Y1NuOFpkTUFlLUR3OFREdnIxT1ZDTVg0UXc?oc=5","date":"2025-10-13","type":"pipeline","source":"Drug Discovery News","summary":"New vaccine pills could replace intramuscular shots - Drug Discovery News","headline":"New vaccine pills could replace intramuscular shots","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPRWNpT3haVHFrNnpBNjhSNFZVSFFFRTN3YS1RTUpCTGFzTlRLT0Z1NFJLYzlNQU1hR3d0c1RhcGxNVkFBV2w0SlNtRVFYbWhDSlNUNHd5aWFmWlVReVdZeW8zOVJIWTdDejlta3FldU5WdjNJUGRBb05qZHZzREhRQ3NPc3U5cGxLR2REb3d2OGEwZw?oc=5","date":"2025-10-01","type":"pipeline","source":"Pharma Voice","summary":"AstraZeneca’s at-home flu vaccine is a breakthrough that could pave the way for others - Pharma Voice","headline":"AstraZeneca’s at-home flu vaccine is a breakthrough that could pave the way for others","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNSFBYSVc5UGpTenJaSk9Cc2JhU2NkYjNIY1pPRXFORHVxTUJZT0xuZVkyOER6Y3N1VXFlNTBadFBzZU01Znc3UFNhWGI5M3BiZnhic1o1X2FuNHBMY1NYbVdnZE9PR3doQk5tOFNKVXFfS3FhTHA0cXE0a0NtSzBubmhuMlY0S2ZkdDh4bmtQYWJsLXpuU0V3Y0dqeTFUTm1tU0piZFdmcjhhbG5wa2hyRWltMGZ6WWtyNjFQaERpUzdXcV84U2ln?oc=5","date":"2025-08-14","type":"trial","source":"Reuters","summary":"US orders Vaxart to stop COVID-19 trial amid mRNA wind down - Reuters","headline":"US orders Vaxart to stop COVID-19 trial amid mRNA wind down","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxObEJQV2JqaVE0bnZRQU1NRUZ6amc0M2c0SFQwbTl0Szdsc3V0NWZSWDZkMFlaMmhJc0RhX25wdEhlaHhZdzEzVUhvby1rTjRfN0piMnA4aDl3Mm9fOEljS3k2bnpwdFNoNmlvUEpwNWxJbE5PZUxjdGxqMjR3OWhTTFRXcHRRdGhFSjVldzd4UzNWa2RSRHNrVDVzVGtPTnc4UFRtQ3Nxa2FKSnpETzA1dg?oc=5","date":"2025-08-12","type":"pipeline","source":"Fierce Biotech","summary":"Vaxart seeks answers as BARDA funding for stop-start vaccine project dries up again - Fierce Biotech","headline":"Vaxart seeks answers as BARDA funding for stop-start vaccine project dries up again","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQMVozS3kweVU1LXJrLXBMMnhtazNSRG9temZVWXh4OEFTYzk3SnJ6T0JlS2Npb0U0OG5lSUJ6Q3lKRVhGWEp5V01uQWg3UEdOUE5RUWo2X09IdmRFLUtubXozZGdtVVFKVXZ6M2xQTWRsUHBhYk9pZUh5bzNjSG9VOXV3Z3hFV1NNczdRMmotNnN1V053NlBDSEFhXzJVcEZLaFNwbU9nRVhnREt5cWVTWGxuRW4?oc=5","date":"2025-08-12","type":"trial","source":"BioPharm International","summary":"After mRNA Rollback, BARDA Pulls Plug on Vaxart Oral COVID Vaccine Trial - BioPharm International","headline":"After mRNA Rollback, BARDA Pulls Plug on Vaxart Oral COVID Vaccine Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1OTFl2djVINmVnazN1WGFLeEo2T0NJeXFId2pRZVpHakg2dDFVSUtSN1g5NS1QdDA2X1FIdGk2ZmJwdXAtNnhoY182X1NiN2dUVnZr?oc=5","date":"2025-06-11","type":"trial","source":"FirstWord Pharma","summary":"Vaccine readouts from Vaxart's norovirus pill, Novavax's COVID-19/flu combo - FirstWord Pharma","headline":"Vaccine readouts from Vaxart's norovirus pill, Novavax's COVID-19/flu combo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQQW1BUzdQVnd3VkJsLU9NOU10X3BFM1p3LS1kdHFRTDhxMWZvb1M0WmE0QW1UaTM2NmNFeC1qYU1kU1ZkRUtHazUweXItZGRzUmhnNEdHcFFuZm1pVlNUTEZTd3hiSUdpNDRIWkxkaTRhajZ0Nnd6aFNtTG02ekQ2SjlvNHEzOTJSSUpuMk56UW45Z1FuQjVSM3N3STdnbmtvUjM5Yw?oc=5","date":"2025-05-27","type":"pipeline","source":"BioSpace","summary":"4 Biotechs Caught Up in Uncertain COVID-19 Vaccine Landscape - BioSpace","headline":"4 Biotechs Caught Up in Uncertain COVID-19 Vaccine Landscape","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNbXBVbUNiU1NlZjV2eGhNd0kzcmo1SGpfMEFtV0FZbW5LMncxT3hfVUtvUmI4Tm9RNDRIMXNnSVVKWEtGOFFFU2syMGRCSVYtXzVpU2xTdXMyZUp1eFBVOVdQdEs4QlZveGtfUEpzU0lVamZ1RnZNb3Y5NXFjTkx4Rjhocl9EZmhGQ0xiYkJqY0p2XzNydFNxU3BWbzYybmJCZGJna2I4OGMtMGM0bWhz?oc=5","date":"2025-05-09","type":"pipeline","source":"The Business Journals","summary":"'It's a mess out there': More biotech layoffs mean stiff competition for jobs at emerging companies - The Business Journals","headline":"'It's a mess out there': More biotech layoffs mean stiff competition for jobs at emerging companies","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":1,"marketed":1,"phase_1":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":237258000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":237258000,"period":"2025-12-31"},{"value":28700000,"period":"2024-12-31"},{"value":28700000,"period":"2024-12-31"},{"value":7379000,"period":"2023-12-31"},{"value":4159000,"period":"2018-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":201576000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":16327000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":186079000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}